Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) announced that the U.S. Food and Drug Administration (FDA) decided to remove its partial clinical hold on the company’s studies investigating magrolimab in combination with azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following its review of the comprehensive safety data from each trial.
“This is a significant milestone for Gilead and, more importantly, for patients diagnosed with these cancers,” Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences, said.
GILD shares are down 15% year-to-date.
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.